Health AI Register Logo
ProductsPlatformsCompaniesNewsContact
ProductsPD-L1 APP, NSCLC

Vendor source

Reviewed 21 Jul 2026

Completeness Strong (69%)

PD-L1 APP, NSCLC

Visiopharm

Fully automated quantification of positively and negatively stained tumor cells in whole slide images stained with PD-L1 IHC and calculation of the Tumor Proportion Score (TPS).

Supported by 1 paper

Key features

calculation of the TPS (%)

Cell detection inside the invasive tissue

fully automated tissue and tumor detection

Quantification of positive vs negative cells

General Information

Product name

PD-L1 APP, NSCLC

Company

Modality

Histopathology

Main task

Scoring (IHC quantification)

Subspeciality

Pulmonary pathology

Organ/Specimen source

Not specified

Disease targeted

Non-Small Cell Lung Cancer (NSCLC)

Specimen type

Biopsy(ies), Resection(s)

Staining

IHC

Stain subtype

PD-L1

Regulatory Information

CE-IVD Certification

Pathway:

In Vitro Diagnostic Regulation (IVDR)

Class:

Class C

Verified by Health AI Register

Scanner Brands Certified for Use (CE-IVD)

Hamamatsu, Philips

Scanner Models Certified for Use (CE-IVD)

Hamamatsu MD scanner (S20MD, S60MD, or S360MD), Philips IntelliSite Ultra Fast Scanner (UFS)

Other certifications

Not specified

Evidence & Research

Technical Specifications

Patient population age

Not specified

Input

Whole slide image, 20x magnification

Input format

Not specified

Output

Segmentation overlay, number of total tumor nuclei, TPS (%)

Output format

Not specified

Integration

Integration via AI marketplace or distribution platform, Integration with IMS (Image Management System), Integration with LMS (Laboratory Management System), Stand-alone third party application, Stand-alone webbased

Deployment

Cloud-based, Hybrid, Locally on dedicated hardware, Locally virtualized (virtual machine, docker)

Trigger for analysis

Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload

Processing time

1 - 10 minutes

Population

Patients with Non-Small Cell Lung Cancer (NSCLC)

Viewer systems

Not specified

Market Presence

On market since

11.2023

AI Platforms

Paige, PathAI AISight, Proscia, Sectra Amplifier Store

Resellers

Agilent, Proscia

Countries present

EU, UK

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Subscription

Based on

Number of analyses

Source: Vendor | First published: Jul 30, 2025 | Last updated: Jul 21, 2026